Skip to main content
OpenTrials
Completed

NCT Number: NCT07384299

Impact of Skin Type on Wonud Healing and Scarring Following Facial Skin Surgery

The goal of this observational study is to learn how an individual's skin type influences the wound healing process and scar formation in Chinese patients undergoing facial dermatologic surgery. The main questions it aims to answer are:

How does skin type affect the quality of wound healing after facial surgery?

How does skin type affect the formation of hypertrophic scars after facial surgery?

Researchers will compare groups of patients with different skin types (classified by the Baumann Skin Type) to see if there are significant differences in their healing outcomes and scar characteristics.

Participants in this study will:

Receive standard facial dermatologic surgery as part of their clinical care.

Have their skin type assessed preoperatively.

Undergo scheduled postoperative follow-up assessments at 7 and 90 days to evaluate wound healing and scar development using standardized scales.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Nevus Cicatrix Cyst Cysts Fibrosis Keratosis Keratosis, Seborrheic Lipoma Neoplasms Neoplasms by Histologic Type Neoplasms, Adipose Tissue Neoplasms, Connective and Soft Tissue Nevi and Melanomas Pathologic Processes Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Scar Seborrheic Keratosis (SK) Skin Diseases Skin and Connective Tissue Diseases

Age range

14 year–60 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Not Appicable

Wuhan, Hubei, 430022, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged between 14 and 60 years.
  • Clinically and postoperatively pathologically diagnosed with a facial benign tumor (e.g., melanocytic nevus, sebaceous cyst, seborrheic keratosis, etc.) and having undergone standard surgical treatment.
  • Voluntary participation in this study with written informed consent obtained.
  • Commitment to comply with all study protocols and to complete all follow-up visits and data collection procedures.

Exclusion criteria

  • Clinically or postoperatively diagnosed with a facial malignant tumor.
  • Wounds requiring staged excision or planned for secondary intention healing.
  • Surgical site located on or adjacent to the mucosal surface.
  • Known history of allergy to any medications or dressings to be used during or after surgery.
  • Presence of systemic diseases that significantly impair wound healing (e.g., poorly controlled diabetes, immunodeficiency disorders, active infections).
  • Current use of medications affecting wound healing or scar formation (e.g., long-term systemic corticosteroids, immunosuppressants).
  • Pregnancy or lactation.
  • Refusal to provide written informed consent, or anticipated inability to comply with study follow-up and data collection.
  • Concurrent participation in another interventional clinical trial.
  • Any other condition deemed by the investigator as likely to interfere with study results or increase participant risk.

Treatment and study plan

Primary outcomes

  1. Patient and Observer Scar Assessment Scale version 2.0 (POSAS 2.0)

    Time frame: 3-month follow-up

    This scale comprises two separate subscales: the Observer Scar Assessment Scale (completed by the clinician) and the Patient Scar Assessment Scale (completed by the participant). The Observer Scale evaluates six items (vascularity, pigmentation, thickness, relief, pliability, and surface area) on a scale from 1 ("like normal skin") to 10 ("the worst scar imaginable"), with a total score ranging from 6 (best) to 60 (worst). The Patient Scale evaluates six items (pain, itching, color, stiffness, thickness, and irregularity) on a scale from 1 ("no, not at all") to 10 ("yes, very much"), with a total score also ranging from 6 (best) to 60 (worst). For both subscales, a higher score indicates a worse scar quality.

  2. modified Stony Brook Scar Evaluation Scale (mSBSES)

    Time frame: 3-month follow-up

    Evaluations were independently performed by two clinicians who were blinded to group allocation. The scale comprises four items: scar width, height, color, and suture marks. Each item is scored from 0 to 2 points, where a score of 2 represents the closest resemblance to normal skin, and 0 represents the worst appearance. The total score ranges from 0 to 8, with a higher score indicating a more ideal scar appearance.

Secondary outcomes

  1. Incidence of Postoperative Edema

    Time frame: 7-day follow-up

    Assessed by direct clinical examination. Unit: % of participants with the presence of edema.

  2. Incidence of Wound Suppuration

    Time frame: Assessed by direct clinical examination. Unit: % of participants with the presence of suppuration.

    7-day follow-up

  3. Incidence of Peri-wound Erythema

    Time frame: 7-day follow-up

    Assessed by direct clinical examination. Unit: % of participants with the presence of erythema.

  4. Incidence of Wound Tenderness

    Time frame: 7-day follow-up

    Assessed by patient report. Unit: % of participants reporting tenderness.

  5. Incidence of Postoperative Hemorrhage

    Time frame: 7-day follow-up

    Assessed by direct clinical examination. Unit: % of participants with active bleeding or hematoma formation.

  6. Incidence of Peri-wound Ecchymosis

    Time frame: 7-day follow-uo

    Assessed by direct clinical examination. Unit: % of participants with the presence of ecchymosis.

Sponsors and collaborators

Lead sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Other

Registry information

Official study title

Impact of Baumann Skin Type on Wound Healing and Scar Formation Following Facial Skin Surgery

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Feb 3, 2026
Registry last updated
Feb 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.